ABSI - Absci partners with M2GEN to speed up cancer drugs to market
2023-04-04 11:58:02 ET
- Absci Corp ( NASDAQ: ABSI ) has partnered with M2GEN to develop new cancer medicines more rapidly than is currently done.
-
Absci's ( ABSI ) artificial intelligence drug creation platform will use M2GEN's clinical and molecular data set, ORIEN AVATAR, to speed the creation of therapies for a variety of cancers.
-
The companies said that the ORIEN database can help find specific antigens that can be targeted by immunotherapies.
-
Also, Absci ( ABSI ) will tap its reverse immunology technology to initially search the database for antibodies from patients with strong immune responses, and then computationally re-assemble antigen-antibody pairs as potential starting points for drug development.
-
Seeking Alpha's Quant Rating recently downgraded Absci ( ABSI ) to strong sell.
For further details see:
Absci partners with M2GEN to speed up cancer drugs to market